PRINCETON, N.J., May 06, 2017 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced the presentation of additional results of its Phase 3 SECURE trial of its investigational low-dose combination hormone contraceptive patch, Twirla® (AG200-15). Anita Nelson, MD, Professor and Chair of Obstetrics and Gynecology at the College of Osteopathic Medicine …
The post Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017 appeared first on ForexTV.
May 07, 2017 at 12:14AM
from Nasdaq NewsFeed
No comments:
Post a Comment